Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Research Domains
  1. Home
  3. Research Domains

Related Concept Videos

  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Prognostic Value Of Cerebrospinal Fluid Tumor Cell Count In Leptomeningeal Disease From Solid Tumors.
  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Prognostic Value Of Cerebrospinal Fluid Tumor Cell Count In Leptomeningeal Disease From Solid Tumors.

    • Related Experiment Video

    Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
    06:25

    Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

    Published on: March 29, 2024

    869

    Prognostic value of cerebrospinal fluid tumor cell count in leptomeningeal disease from solid tumors.

    Andrew B Barbour1, Barbara Blouw2, Lynne P Taylor3

    • 1Department of Radiation Oncology, University of Washington- Fred Hutchinson Cancer Center, Seattle, WA, USA.

    Journal of Neuro-Oncology
    |March 5, 2024

    View abstract on PubMed

    Summary
    This summary is machine-generated.

    Cerebrospinal fluid tumor cell (CSF-TC) density, identified using the CNSide assay, shows prognostic value in leptomeningeal disease (LMD) from solid tumors. This finding may improve risk stratification and guide treatment decisions for LMD patients.

    Keywords:
    BioceptCNSideCTCCirculating tumor cellsLMDRare cell capture

    More Related Videos

    Lung Tumor Cell Recruitment Assay
    04:28

    Lung Tumor Cell Recruitment Assay

    Published on: February 26, 2019

    5.3K
    Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
    12:52

    Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

    Published on: November 28, 2015

    15.8K

    Related Experiment Videos

    Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
    06:25

    Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

    Published on: March 29, 2024

    869
    Lung Tumor Cell Recruitment Assay
    04:28

    Lung Tumor Cell Recruitment Assay

    Published on: February 26, 2019

    5.3K
    Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
    12:52

    Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

    Published on: November 28, 2015

    15.8K

    Area of Science:

    • Neuro-oncology
    • Cancer diagnostics
    • Molecular pathology

    Background:

    • Leptomeningeal disease (LMD) treatment decisions lack objective prognostic tools, relying on risk stratification.
    • Rare cell capture technology, like the CNSide assay, enhances LMD diagnosis sensitivity for cerebrospinal fluid tumor cells (CSF-TCs).
    • The prognostic significance of CSF-TC density in LMD remains largely unknown.

    Purpose of the Study:

    • To evaluate the prognostic value of CSF-TC density in patients with LMD originating from solid tumors.
    • To determine if CSF-TC density can aid in risk stratification for LMD patients.

    Main Methods:

    • Retrospective cohort study of 31 LMD patients with CNSide assay testing (2020-2023).
    • Univariable and multivariable survival analyses using Cox proportional-hazards modeling.
    • Maximally-selected rank statistics to identify an optimal CSF-TC density cutpoint for survival prediction.

    Main Results:

    • CNSide detected CSF-TCs in 29 of 31 patients (93.5% sensitivity).
    • Median CSF-TC density was 67.8 TCs/mL; median survival was 176 days.
    • CSF-TC density significantly correlated with survival, with an optimal cutpoint of 19.34 TCs/mL.

    Conclusions:

    • CSF-TC density demonstrates potential prognostic value in LMD patients with solid tumors.
    • Incorporating CSF-TC density into risk stratification may enhance clinical decision-making for LMD management.